Eye Specialist Oculis Launching Four Key Clinical Studies
CEO Says Transformative Trials Will Trigger Partnering Talks
The CEO of Oculis tells Scrip the Swiss biotech can become a major ophthalmic player and that its lead asset could become the first topical drug treatment for retinal edema.
